越来越多的分子证据支持EB病毒(EBV)参与喉鳞状细胞癌(LSCC)的发病机制;然而,流行病学数据不一致。在这项回顾性病例对照研究中,我们旨在确定EBV感染是否与LSCC的风险和预后相关.EBV感染的患病率,使用EBVDNA聚合酶链反应分析,在42例台湾新诊断的原发性LSCC患者中,与39名年龄和性别匹配的无癌症对照患者相比(48%与19%)。此外,使用原位杂交检测到的大部分EBER信号位于肿瘤浸润淋巴细胞的细胞核.在多变量分析中,EBVDNA阳性,年龄≥55岁,吸烟,和高BCL-2,B2M,和CD161表达(使用免疫组织化学评估)被确定为LSCC的独立危险因素。此外,5年局部复发和无病生存率分别为34%和58%,分别,高EBER信号和低CD3表达独立预测5年局部复发和无病生存。我们全面的分析数据准确地识别了有LSCC发展风险的患者,局部复发,或无病生存。这项研究中获得的信息提高了我们对LSCC中EBV感染的理解,并可指导LSCC患者的精准医疗。
Mounting molecular evidence supports Epstein-Barr virus (EBV) involvement in the pathogenesis of laryngeal squamous cell carcinoma (LSCC); however, the epidemiological data are inconsistent. In this retrospective case-control
study, we aimed to determine whether EBV infection underlies the risk and prognosis of LSCC. The prevalence of EBV infection, as analyzed using an EBV DNA polymerase chain reaction assay, was significantly higher in 42 Taiwanese patients with newly diagnosed primary LSCC, compared to 39 age- and sex-matched control patients without cancer (48% vs. 19%). Furthermore, most of the EBER signals detected using in situ hybridization were localized to the nuclei of tumor-infiltrating lymphocytes. In multivariate analysis, EBV DNA positivity, age ≥ 55 years, cigarette smoking, and high BCL-2, B2M, and
CD161 expression (assessed using immunohistochemistry) were identified as independent risk factors for LSCC. Furthermore, five-year local recurrence and disease-free survival rates were 34% and 58%, respectively, with a high EBER signal and low CD3 expression independently predicting five-year local recurrence and disease-free survival. Our comprehensive profiling data accurately identified patients at risk for LSCC development, local recurrence, or disease-free survival. The information obtained in this
study improves our understanding of EBV infection in LSCC, and may guide precision medicine for patients with LSCC.